- Home
- PRI vs VRNA Comparison
PRI vs VRNA Comparison
Compare PRI & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRI
- VRNA
- Stock Information
- Founded
- PRI 1927
- VRNA 2005
- Country
- PRI United States
- VRNA United Kingdom
- Employees
- PRI N/A
- VRNA N/A
- Industry
- PRI Life Insurance
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- PRI Finance
- VRNA Health Care
- Exchange
- PRI Nasdaq
- VRNA Nasdaq
- Market Cap
- PRI 9.0B
- VRNA 8.3B
- IPO Year
- PRI N/A
- VRNA 2017
- Fundamental
- Price
- PRI $277.81
- VRNA $90.48
- Analyst Decision
- PRI Buy
- VRNA Strong Buy
- Analyst Count
- PRI 7
- VRNA 9
- Target Price
- PRI $308.00
- VRNA $112.56
- AVG Volume (30 Days)
- PRI 200.8K
- VRNA 1.2M
- Earning Date
- PRI 08-06-2025
- VRNA 08-07-2025
- Dividend Yield
- PRI 1.50%
- VRNA N/A
- EPS Growth
- PRI N/A
- VRNA N/A
- EPS
- PRI 14.79
- VRNA N/A
- Revenue
- PRI $3,219,572,000.00
- VRNA $118,535,000.00
- Revenue This Year
- PRI $2.48
- VRNA $891.79
- Revenue Next Year
- PRI $4.58
- VRNA $78.94
- P/E Ratio
- PRI $18.78
- VRNA N/A
- Revenue Growth
- PRI 12.60
- VRNA N/A
- 52 Week Low
- PRI $230.98
- VRNA $14.15
- 52 Week High
- PRI $307.91
- VRNA $99.01
- Technical
- Relative Strength Index (RSI)
- PRI 55.29
- VRNA 56.61
- Support Level
- PRI $262.96
- VRNA $92.88
- Resistance Level
- PRI $275.20
- VRNA $99.01
- Average True Range (ATR)
- PRI 4.49
- VRNA 3.42
- MACD
- PRI 1.26
- VRNA -0.78
- Stochastic Oscillator
- PRI 78.23
- VRNA 25.24
About PRI Primerica Inc.
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the US.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.